Mechanisms and functions of inflammasomes

M Lamkanfi, VM Dixit - Cell, 2014 - cell.com
Recent studies have offered a glimpse into the sophisticated mechanisms by which
inflammasomes respond to danger and promote secretion of interleukin (IL)-1β and IL-18 …

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

CA Dinarello, A Simon… - Nature reviews Drug …, 2012 - nature.com
Abstract Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain
thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory …

Systemic amyloidosis

AD Wechalekar, JD Gillmore, PN Hawkins - The Lancet, 2016 - thelancet.com
Tissue deposition of protein fibrils causes a group of rare diseases called systemic
amyloidoses. This Seminar focuses on changes in their epidemiology, the current approach …

The NLRP3 inflammasome: contributions to inflammation-related diseases

Y Chen, X Ye, G Escames, W Lei, X Zhang, M Li… - Cellular & molecular …, 2023 - Springer
The NOD-like receptor protein 3 (NLRP3) inflammasome is a protein complex that regulates
innate immune responses by activating caspase-1 and the inflammatory cytokines …

NLRP3 inflammasome in neurological diseases, from functions to therapies

L Song, L Pei, S Yao, Y Wu, Y Shang - Frontiers in cellular …, 2017 - frontiersin.org
Neuroinflammation has been identified as a causative factor of multiple neurological
diseases. The nucleotide-binding oligomerization domain-, leucine-rich repeat-and pyrin …

Treating inflammation by blocking interleukin-1 in humans

CA Dinarello, JWM van der Meer - Seminars in immunology, 2013 - Elsevier
IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific
IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL …

The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory …

M Romano, ZS Arici, D Piskin, S Alehashemi… - Annals of the …, 2022 - ard.bmj.com
Background The interleukin-1 (IL-1) mediated systemic autoinflammatory diseases,
including the cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor …

Anakinra therapy for non-cancer inflammatory diseases

G Cavalli, CA Dinarello - Frontiers in pharmacology, 2018 - frontiersin.org
Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-
1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory …

Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease

ME Haque, M Akther, M Jakaria, IS Kim… - Movement …, 2020 - Wiley Online Library
Excessive activation of microglia and subsequent release of proinflammatory cytokines play
a crucial role in neuroinflammation and neurodegeneration in Parkinson's disease (PD) …

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

N Ter Haar, H Lachmann, S Özen, P Woo… - Annals of the …, 2013 - ard.bmj.com
Objective To evaluate the response to treatment of autoinflammatory diseases from an
international registry and an up-to-date literature review. Methods The response to treatment …